MainPointe signs with Acura for NEXAFED marketing rights

Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC recently entered a licensing agreement that will give MainPointe exclusive marketing rights for NEXAFED and NEXAFED Sinus in the United States and Canada.
"MainPointe is an emerging OTC pharmaceutical company that brings added leverage to our NEXAFED business," Acura President and CEO Bob Jones said in a statement. "With additional products in distribution and new customer contacts, MainPointe is well positioned to expand on the U.S. pharmacy distribution achieved by Acura over the past several years."
Through the agreement, which involves an upfront cash payment of $2.5 million to Acura, MainPointe will receive all manufacturing and commercialization activities for the products. MainPointe will deliver a 7.5 percent royalty on all commercial sales of the products to Acura.
NEXAFED, a pseudoephedrine-containing brand, uses specific Acura technology to disrupt the extraction and conversion of pseudoephedrine into methamphetamine.
"Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities," MainPointe's Chairman and CEO John Schulte said. "The NEXAFED products have proven to be a success in curbing this costly problem and we look forward to driving this business forward."